Safety and efficiency of allogenic natural killer cell therapy in relapsed/refractory multiple myeloma and high-risk multiple myeloma patients

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 15 人开始时间: 待定最近更新: 2023年10月16日

适应症

试验速览

暂无简介。

•The presence of at least one of the followings: more than 0.5 g/dl M-protein in serum protein electrophoresis, excretion of at least 200 mg of M-protein in urine, more than 10 mg/dL immunoglobulin free light chain in serum
•Relapse confirmation based on International Myeloma Working Group
•Refractory to at least two treatment regimens (an immunomodulatory drug, a proteasome inhibitor drug)
•High-risk multiple myeloma according to the International Myeloma Working Group: recurrence within 12 months after the previous autologous transplant or progression of the disease within 1 year since the diagnosis of the disease or the presence of any of the high-risk cytogenetic cases including t(4;14), t (14;16), (14;20)t, chromosome gain/amplification (+1q21), deletion of the short arm of chromosome 17 (del(17p))

•Insufficiency of engraftment parameters: WBC less than1000/µl, Platelets less than 20000/µl, Hemoglobin less than 8g/dL
•Total bilirubin greater than 2mg/dL
•Creatinine greater than 2mg/dL
•Renal clearance less than 30 mL/min
•Liver enzymes more than 2.5 times the upper limit of normal

发起方